This story is from November 19, 2019
Advent buys majority stake in Bharat Serums
Mumbai: Private equity major
While Orbimed and Kotak held around 23% in Bharat Serums, the remaining shares were held by the Daftary family. The company was founded in 1971 by Vinod Daftary and is now run by his sons, chairman Bharat Daftary and vice-chairman Gautam Daftary.
The company, which saw its top line increase by about 18% to Rs 888 crore in FY19, makes and markets biopharma products in women’s healthcare, assisted reproductive treatment, critical care and emergency medicine.
“The group has also continuously invested in research and development resulting in creation of over 30 products in therapeutic segments. It also holds eight patents in India, the US, and Europe,” said a Crisil rating report, adding that it has a profit margin of about 10.4%.
The deal is the fourth major investment by Advent in India this year after it acquired majority in ‘Crax’ snacks maker DFM Foods, diversified financial services player Aditya Birla Capital besides innerwear makers Dixcy and Enamor. Globally, Advent has invested $9 billion in the pharma space in the past 29 years.
“Drawing on our deep experience in pharmaceuticals and our global platform, we see significant opportunity to further strengthen the company’s leadership position in India, particularly in women’s health, and scale its presence in emerging markets around the world,” said Advent’s India head Shweta Jalan.
Stay informed with the latest Business News on Times of India. Explore updates on International Business, gain insights with Financial Literacy tips, and make use of Financial Calculators. Don’t forget to check the list of Bank Holidays in 2025, including Bank Holidays in January.
Ready to Master Stock Valuation? ET’s Workshop is just around the corner!
Advent
International has picked up a majority stake in Mumbai-basedBharat Serums and Vaccines
at an enterprise valuation of about $500 million from its promoters, the Daftary family, and existing investors Orbimed and Kotak Private Equity. While the firm did not disclose financial details of the deal, Advent is believed to have picked up about 60% stake in the 48-year-old biopharmaceuticals company, pegging the deal size at over $250 million.The company, which saw its top line increase by about 18% to Rs 888 crore in FY19, makes and markets biopharma products in women’s healthcare, assisted reproductive treatment, critical care and emergency medicine.
“The group has also continuously invested in research and development resulting in creation of over 30 products in therapeutic segments. It also holds eight patents in India, the US, and Europe,” said a Crisil rating report, adding that it has a profit margin of about 10.4%.
The deal is the fourth major investment by Advent in India this year after it acquired majority in ‘Crax’ snacks maker DFM Foods, diversified financial services player Aditya Birla Capital besides innerwear makers Dixcy and Enamor. Globally, Advent has invested $9 billion in the pharma space in the past 29 years.
“Drawing on our deep experience in pharmaceuticals and our global platform, we see significant opportunity to further strengthen the company’s leadership position in India, particularly in women’s health, and scale its presence in emerging markets around the world,” said Advent’s India head Shweta Jalan.
Stay informed with the latest Business News on Times of India. Explore updates on International Business, gain insights with Financial Literacy tips, and make use of Financial Calculators. Don’t forget to check the list of Bank Holidays in 2025, including Bank Holidays in January.
Ready to Master Stock Valuation? ET’s Workshop is just around the corner!
Popular from Business
- Stock market today: BSE Sensex closes over 1,400 points up; Nifty50 above 24,150 - top reasons for New Year bull party
- Adani Group bribery allegations: Chandrababu Naidu takes a step back, says no action can be taken until concrete proof
- Small savings schemes: What are the latest interest rates for post office schemes like PPF, SSY, SCSS for Jan-March 2025?
- Gold prices: Will 2025 be a golden year for gold? Here’s why experts are bullish on the yellow metal
- India’s exports wonders! Humble banana, ghee, office stationery see rapid growth in new markets
end of article
Trending Stories
- Small savings schemes: What are the latest interest rates for post office schemes like PPF, SSY, SCSS for Jan-March 2025?
- India’s exports wonders! Humble banana, ghee, office stationery see rapid growth in new markets
- How to apply for a minor PAN card? Know the process, documents required and other key details
- Stock market today: BSE Sensex opens over 200 points up; Nifty50 above 23,800
- Adani group to exit Adani Wilmar, sell stake to raise over $2 billion
- Adani to exit Wilmar Joint Venture, to sell 44% in FMCG company for $2 billion
- Stock market today: BSE Sensex slips over 350 points; Nifty50 below 23,600
Visual Stories
- 9 Ways Being Proactive Can Improve Your Grades
- 9 Common Exam Revision Mistakes You Should Avoid
- 10 Effective Tips for Students to Improve Reading Speed
- 8 Popular books by Jimmy Carter that are a must read for students
- Top-selling hatchbacks in November 2024: New Swift, Tiago, Glanza and more
TOP TRENDS
UP NEXT
Start a Conversation
Post comment